GFAP即时检测用于胶质母细胞瘤快速诊断的前瞻性评估
该前瞻性研究纳入101例新诊断颅内占位疑似脑肿瘤患者,术前用i-STAT Alinity检测血浆GFAP。胶质母细胞瘤患者GFAP中位数610 pg/mL,显著高于其他肿瘤的81.5 pg/mL(p<0.001); cut-off 191 pg/mL时敏感度84%、特异度75%。GFAP>1000 pg/ml提示胶质母细胞瘤特异度95%、阳性预测值82%,排除淋巴瘤后特异度升至96%、PPV升至93%。
要点
- 血浆GFAP即时检测可辅助鉴别胶质母细胞瘤与其他脑肿瘤。
- cut-off 191 pg/mL敏感度84%、特异度75%。
- GFAP>1000 pg/ml特异度95%、PPV 82%。
核心结论
- GFAP即时检测对胶质母细胞瘤具有较高诊断准确性,有望优化脑肿瘤诊疗流程。
研究设计与样本
- 前瞻性纳入101例新诊断颅内占位疑似脑肿瘤患者,术前采集血样,以最终组织病理诊断为金标准。
主要发现
- 胶质母细胞瘤患者(n=37)GFAP中位数610 pg/mL(IQR 263.5–1877.5),其他肿瘤(n=64)为81.5 pg/mL(IQR 40.3–197.3),p<0.001。
- cut-off 191 pg/mL诊断胶质母细胞瘤的敏感度为84%、特异度为75%。
- GFAP>1000 pg/ml提示胶质母细胞瘤的特异度为95%、阳性预测值为82%。
- 排除淋巴瘤后,GFAP>1000 pg/ml的特异度升至96%、阳性预测值升至93%。
关键数值与推荐
- GFAP cut-off 191 pg/mL:敏感度84%、特异度75%。
- GFAP>1000 pg/ml:特异度95%、PPV 82%;排除淋巴瘤后特异度96%、PPV 93%。
临床怎么用
- 对于疑似脑肿瘤患者,术前GFAP即时检测可辅助快速鉴别胶质母细胞瘤,尤其高值(>1000 pg/ml)时特异度高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Glioblastoma is the most common and the most aggressive malignant primary brain tumor. The diagnosis is made by histopathological analysis following stereotactic biopsy or tumor resection. However, rapid diagnostic clarity is often required before histology becomes available. Glial fibrillary acidic protein (GFAP) has been studied as a blood biomarker for glioblastoma using conventional immunoassays. The aim of this study was to test the diagnostic value of a GFAP point-of-care device to differentiate glioblastoma from other brain tumors. METHODS: Patients admitted to our hospital with a newly diagnosed intracranial lesion suspicious for a brain tumor were enrolled prospectively. Blood samples were collected prior to diagnostic and therapeutic procedures. Plasma GFAP measurements were performed using the TBI plasma test on the i-STAT Alinity® (Abbott) device. The gold standard was the final histopathological diagnosis. RESULTS: We prospectively enrolled 101 patients (mean age 63 ± 17 years, 44.6% female). GFAP plasma levels were significantly higher in patients with glioblastoma (n = 37; median 610 pg/mL [interquartile range 263.5–1877.5]) compared to other tumors (n = 64; 81.5 pg/mL [40.3–197.3]; p < 0.001). A cut-off point of 191 pg/mL revealed a sensitivity of 84% and a specificity of 75% for diagnosing glioblastoma. A GFAP plasma concentration of > 1000 pg/ml was indicative of glioblastoma with a specificity of 95% and a positive predictive value (PPV) of 82%. Excluding lymphomas further increased the specificity to 96% and PPV to 93%. CONCLUSION: GFAP measurements using a point-of-care device indicate glioblastoma with high diagnostic accuracy. GFAP testing has the potential to streamline the work-up of brain tumors.
引用
- Blums K, Kalra LP, Nerntengian N, et al. Prospective evaluation of GFAP point-of-care testing for rapid diagnosis of glioblastoma. J Neurooncol. 2026. PMID: 41762323. doi:10.1007/s11060-026-05479-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。